We demonstrate that BCL2 inhibition, alone or combined with Nilotinib have been effective on CML CD34-positive progenitors and Ph+ B-ALL cells but failed to interfere with self-renewal properties of CML primitive cells. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.